The use of strontium 89 for palliation of pain from bone metastases associated with hormone-refractory prostate cancer.
Crawford
E D
ED
Division of Urology, University of Colorado Health Sciences Center, Denver.
Kozlowski
J M
JM
Debruyne
F M
FM
Fair
W R
WR
Logothetis
C J
CJ
Balmer
C
C
Robinson
R G
RG
Porter
A T
AT
Kirk
D
D
D000368:Aged; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D010148:Intractable Pain / Q000209:etiology / Q000532:radiotherapy*; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000628:therapy; D013326:Strontium Radioisotopes / Q000627:therapeutic use*; D017211:Treatment Failure
D006728:Hormones; D013326:Strontium Radioisotopes